PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Dyslipidaemia in type 2 diabetes: cardiovascular risk assessment and management

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016

PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

JCM, Free Full-Text

Full article: Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

PDF) Statin-induced myopathy: A review and update

Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations: Molecular Therapy

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease

Impact of critical illness on cholesterol and fatty acids: insights into pathophysiology and therapeutic targets, Intensive Care Medicine Experimental